U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07066436) titled 'ImmunoMRI for Assessment of Tumor-associated Macrophages' on June 24.
Brief Summary: About 35% of patients with a type of blood cancer called diffuse large B-cell lymphoma don't respond well to standard treatment or their cancer comes back. When this happens, newer treatments like CAR T-cell therapy (using modified immune cells) or bispecific antibodies (special proteins that help the immune system fight cancer) are an option. However, these treatments are only successful in about half the patients. It is currently difficult to predict which patients will respond to these treatments or experience serious side effects. This makes it ...